Here is Why Growth Investors Should Buy Globus Medical (GMED) Now
Globus Medical (GMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Zacks Investment Research8/17/2026Positive
GMED
Globus MedicalNYSEHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$11.43B
P/E Ratio
21.99
EPS
$3.87
Beta
0.95
52W High
$101.40
52W Low
$54.15
50-Day MA
$80.00
200-Day MA
$85.08
Dividend Yield
—
Profit Margin
17.00%
Forward P/E
18.80
PEG Ratio
1.73
About Globus Medical
Globus Medical, Inc., a medical device company, develops and markets healthcare solutions for patients with musculoskeletal disorders. The company is headquartered in Audubon, Pennsylvania.
Fundamentals
| Revenue (TTM) | $3.14B |
| Gross Profit (TTM) | $2.17B |
| EBITDA | $1.01B |
| Operating Margin | 24.80% |
| Return on Equity | 11.80% |
| Return on Assets | 8.74% |
| Revenue/Share (TTM) | $23.32 |
| Book Value | $34.88 |
| Price-to-Book | 2.42 |
| Price-to-Sales (TTM) | 3.63 |
| EV/Revenue | 3.513 |
| EV/EBITDA | 11.59 |
| Quarterly Earnings Growth (YoY) | -26.20% |
| Quarterly Revenue Growth (YoY) | 5.90% |
| Shares Outstanding | $111.83M |
| Float | $110.20M |
| % Insiders | 0.61% |
| % Institutions | 92.03% |
Historical Volatility
HV 10-Day
26.66%
HV 20-Day
27.00%
HV 30-Day
37.00%
HV 60-Day
40.21%
HV Rank
53.2%
Volatility is currently contracting
Analyst Ratings
Consensus ($103.23 target)
3
Strong Buy7
Buy5
HoldLatest News
Globus Medical (GMED) Upgraded to Strong Buy: Here's Why
Globus Medical (GMED) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research8/11/2026Positive
GMED vs. ITGR: Which Stock Is the Better Value Option?
Investors interested in Medical - Instruments stocks are likely familiar with Globus Medical (GMED) and Integer (ITGR). But which of these two stocks is more attractive to value investors?
Zacks Investment Research8/11/2026Positive
GMED Q2 Earnings Call Highlights Margin Gains and Revenue Caution
Globus Medical raises 2026 EPS guidance after Q2 margin gains and spine growth while holding sales guidance steady amid Nevro and Enabling Technologies risks.
Zacks Investment Research8/7/2026Positive
Globus Medical Reports Second Quarter 2026 Results
AUDUBON, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the second quarter ended June 30, 2026.
GlobeNewsWire8/6/2026Neutral
Why Globus Medical (GMED) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research8/6/2026Positive
What to Expect From These 2 MedTech Stocks This Earnings Season?
Globus Medical and Resmed enter the earnings season with growth drivers intact despite tariff, inflation and hospital spending pressures.
Zacks Investment Research8/5/2026Neutral
Unlocking Q2 Potential of Globus Medical (GMED): Exploring Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Globus Medical (GMED) for the quarter ended June 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Zacks Investment Research8/5/2026Neutral
GMED's Q2 Earnings on Deck: Will Enabling Technologies Lead Results?
Globus Medical will report Q2 results on Aug. 6. Investors will be keen to know whether Enabling Technologies and Spine strength aid revenue & earnings growth.
Zacks Investment Research7/31/2026Positive
Reasons to Retain Globus Medical Stock in Your Portfolio for Now
GMED is gaining share in musculoskeletal solutions with strong implant and trauma growth, backed by a debt-free balance sheet despite cost and FX pressures.
Zacks Investment Research7/22/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GMED and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026